Tillkännagivande • Jun 30
PT Barito Pacific Tbk announces Annual dividend, payable on July 29, 2026 PT Barito Pacific Tbk announced Annual dividend of IDR 1.6300 per share payable on July 29, 2026, ex-date on July 06, 2026 and record date on July 07, 2026. Board Change • May 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Tillkännagivande • May 20
PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026 PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026. Tillkännagivande • Feb 04
PT Barito Pacific Tbk (IDX:BRPT) announces an Equity Buyback for IDR 1,000,000 million worth of its shares. PT Barito Pacific Tbk (IDX:BRPT) announces a share repurchase program. Under the plan, the company will repurchase up to IDR 1,000,000 million worth of its shares. The program will be fully funded by internal cash balance. The purpose of the program is to provide flexibility to achieve an efficient capital structure and reflect the Company's performance through the company's share price. Repurchased shares will be held as treasury shares and transferred within 3 years of completion. The program will expire on May 3, 2026. Board Change • Dec 30
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Tillkännagivande • May 14
PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025 PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025. Location: jakarta Indonesia Tillkännagivande • Apr 25
PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion. PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion on April 21, 2025. A cash consideration of IDR 90 billion will be paid by PT Buana Primatama Niaga and PT Chandra Daya Investasi for 20,390 shares. The composition of BIP's share ownership after the share acquisition has changed. CDI is now the majority shareholder in BIP, namely 20,399 shares worth IDR 20.39 billion (99.99%). The remaining 1 share (1%) or worth IDR 1 million is owned by BPN. In order to support this transformation, BRPT and GI intend to transfer all share ownership in BIP to the CAP Group and its affiliates, namely BIP and BPN, so that the logistics business line can be more focused on being developed by the CAP Group. The object of this affiliate transaction is all shares owned by BRPT and all shares owned by GI in BIP with a total of 20,400 shares or representing 100% of all shares issued in BIP. The value of this transaction is recorded at IDR 90 billion.
Kantor Jasa Penilai Publik Syarif, Endang & Partners acted as fairness opinion provider for PT Barito Pacific Tbk. Reported Earnings • Nov 01
Third quarter 2024 earnings released: EPS: US$0 (vs US$0 in 3Q 2023) Third quarter 2024 results: EPS: US$0 (in line with 3Q 2023). Revenue: US$517.9m (down 30% from 3Q 2023). Net loss: US$7.69m (down 240% from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. New Risk • Oct 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Reported Earnings • Aug 02
Second quarter 2024 earnings released: EPS: US$0 (vs US$0 in 2Q 2023) Second quarter 2024 results: EPS: US$0 (in line with 2Q 2023). Revenue: US$540.6m (down 25% from 2Q 2023). Net income: US$25.6m (up 262% from 2Q 2023). Profit margin: 4.7% (up from 1.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Tillkännagivande • May 12
PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024 PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024. Buy Or Sell Opportunity • May 07
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 4.3% to €0.049. The fair value is estimated to be €0.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 78%. Revenue is forecast to grow by 13% in a year. Earnings are forecast to grow by 1,155% in the next year. Reported Earnings • May 03
First quarter 2024 earnings released: EPS: US$0 (vs US$0 in 1Q 2023) First quarter 2024 results: EPS: US$0 (in line with 1Q 2023). Revenue: US$618.6m (down 4.9% from 1Q 2023). Net income: US$8.86m (down 62% from 1Q 2023). Profit margin: 1.4% (down from 3.6% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance. Buy Or Sell Opportunity • Apr 02
Now 21% overvalued Over the last 90 days, the stock has fallen 28% to €0.048. The fair value is estimated to be €0.039, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 61%. Revenue is forecast to grow by 4.5% in 2 years. Earnings are forecast to grow by 349% in the next 2 years. Reported Earnings • Mar 30
Full year 2023 earnings released: EPS: US$0 (vs US$0 in FY 2022) Full year 2023 results: EPS: US$0 (in line with FY 2022). Revenue: US$2.76b (down 6.8% from FY 2022). Net income: US$26.1m (up US$24.4m from FY 2022). Profit margin: 0.9% (up from 0.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Buy Or Sell Opportunity • Mar 08
Now 24% overvalued Over the last 90 days, the stock has fallen 46% to €0.051. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years. Buy Or Sell Opportunity • Feb 22
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 5.3% to €0.05. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years. Buy Or Sell Opportunity • Feb 07
Now 34% overvalued after recent price rise Over the last 90 days, the stock has risen 34% to €0.067. The fair value is estimated to be €0.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years. Reported Earnings • Nov 02
Third quarter 2023 earnings released: EPS: US$0 (vs US$0 in 3Q 2022) Third quarter 2023 results: EPS: US$0 (in line with 3Q 2022). Revenue: US$738.1m (down 2.8% from 3Q 2022). Net income: US$5.48m (up 123% from 3Q 2022). Profit margin: 0.7% (up from 0.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings. Reported Earnings • Aug 02
Second quarter 2023 earnings released: EPS: US$0 (vs US$0 in 2Q 2022) Second quarter 2023 results: EPS: US$0 (in line with 2Q 2022). Revenue: US$723.5m (down 10.0% from 2Q 2022). Net income: US$7.08m (up US$7.59m from 2Q 2022). Profit margin: 1.0% (up from net loss in 2Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Reported Earnings • Jun 21
First quarter 2023 earnings released First quarter 2023 results: Revenue: US$650.7m (down 20% from 1Q 2022). Net income: US$23.3m (up 149% from 1Q 2022). Profit margin: 3.6% (up from 1.1% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 02
Second quarter 2022 earnings released: EPS: US$0 (vs US$0.001 in 2Q 2021) Second quarter 2022 results: EPS: US$0 (down from US$0.001 in 2Q 2021). Revenue: US$804.3m (down 3.0% from 2Q 2021). Net loss: US$509.0k (down 101% from profit in 2Q 2021). Revenue is forecast to decline by 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (3 non-independent directors). President Commissioner Prajogo Pangestu is the most experienced director on the board, commencing their role in 1993. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Apr 06
Full year 2021 earnings released: EPS: US$0.001 (vs US$0 in FY 2020) Full year 2021 results: EPS: US$0.001 (up from US$0 in FY 2020). Revenue: US$3.16b (up 35% from FY 2020). Net income: US$109.1m (up 201% from FY 2020). Profit margin: 3.5% (up from 1.6% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.1%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Tillkännagivande • Jul 01
PT Barito Pacific to Be Deleted from Other OTC PT Barito Pacific TBK Ordinary Shares will be deleted from Other OTC effective July 01, 2021. The deletion is due to Inactive Security. Reported Earnings • Apr 04
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$2.33b (down 2.8% from FY 2019). Net income: US$36.3m (down 18% from FY 2019). Profit margin: 1.6% (down from 1.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. 
